[Show abstract][Hide abstract] ABSTRACT: Objective: Obesity increases the risk of atherosclerotic diseases. The relation between carotid intima-media thickness (CIMT) and subclinical atherosclerosis is known. In this study; we investigated the relationship between CIMT and clinical and laboratory parameters related to carotid blood flow. Material and Methods: We enrolled 64 obese and 40 overweight and a total of 104 patients in the study. Body mass index (BMI), waist circumference (WC), hip circumference (HC) and waist to hip ratio (WHR) of the patients were recorded. Patients' fasting blood glucose (FBG), insulin, triglyceride (TG) and LDL-cholesterol (LDL-C) levels were measured. Insulin resistance (HOMA-R) was calculated. Carotid intima-media thickness and blood flow were measured by Doppler ultrasound. Results: The average age was 46.6±11.1 years. The subjects were subdivided into two groups as overweight and obese. FBG, insulin and HOMA-R were elevated in both groups. TG levels were elevated in the obese group, but not in the overweight group. LDL levels were normal in both groups. Increased intima-media thickness was observed in 32 patients. The correlation between carotid blood flow peak systolic velocity (PSV) of 29-127 cm/min (average 74.76 cm/min) and WHR was weak (r=0.37; p=0.030). EDV (11- 51 cm/min, average 31.62+10.52 cm/min) showed weak correlations with BMI and WHR (r=0.33; p=0.170). Conclusion: Ultrasonographic evaluation of atherosclerotic changes in arteries should be used in clinical practice more often, as it is relatively easy and noninvasive. Resistivity index of internal carotid artery may also be used as a marker of atherosclerosis in addition to intima media thickness.
No preview · Article · Jan 2013 · Turkiye Klinikleri Journal of Medical Sciences
[Show abstract][Hide abstract] ABSTRACT: A 25-year-old female patient with Crohn's disease had been using azathioprine and metronidazole for an extended period because of recurrent perianal and rectovaginal fistulae. Infliximab was added to the treatment regimen following postoperative recurrence of a rectovaginal fistula. Upon the development of severe neutropenia and thrombocytopenia after the third dose of infliximab, azathioprine and infliximab were stopped. Neutropenia work-up did not reveal any other cause. Neutropenia was ameliorated with use of granulocyte colony-stimulating factor. Treatment was restarted with infliximab alone upon leakage from the rectovaginal fistula with no hematologic toxicity. This case was considered as a serious adverse effect of infliximab and azathioprine combination therapy.
Full-text · Article · Oct 2011 · The Turkish journal of gastroenterology: the official journal of Turkish Society of Gastroenterology
[Show abstract][Hide abstract] ABSTRACT: Somatostatin receptors have been shown on hepatic stellate cells, and somatostatin infusion has been shown to inhibit hepatic stellate cells activation. We aimed to test the effects of a long-acting somatostatin analogue, lanreotide, on bile duct ligation-induced liver fibrosis in rats.
Thirty-seven Wistar rats were divided into 5 groups as follows: Group 1, bile duct ligation+lanreotide; Group 2, bile duct ligation; Group 3, sham+lanreotide; Group 4, sham; and Group 5, control group. Lanreotide-autogel (20 mg/kg/month) or saline in intraperitoneal doses was administered. Serum biochemical parameters, liver collagen level, and oxidative stress and histological parameters were determined after 28 days.
The tissue collagen level, biochemical parameters (AST, ALT, bilirubins, alkaline phosphatase, γ-glutamyl transpeptidase) and oxidative stress parameters (malondialdehyde, luminal, lucigenin) in the bile duct ligation groups were higher than in the sham-operated and control groups (p<0.001 for all). Lanreotide improved malondialdehyde and glutathione levels in the bile duct ligation+lanreotide group. In histopathological examination, bile duct ligation groups showed stage-3 liver fibrosis, while all the controls were normal. Lanreotide did not improve the liver fibrosis histologically or biochemically.
A monthly active somatostatin analogue, lanreotide, improved malondialdehyde and glutathione; however, it was not able to improve bile duct ligation-induced liver fibrosis in rats. Although lanreotide is a long-acting medication, it did not show anti-fibrotic effects in the model.
Full-text · Article · Sep 2010 · The Turkish journal of gastroenterology: the official journal of Turkish Society of Gastroenterology